CN115956086A - 用于针对癌症及传染病的免疫疗法的融合蛋白 - Google Patents

用于针对癌症及传染病的免疫疗法的融合蛋白 Download PDF

Info

Publication number
CN115956086A
CN115956086A CN202180029571.6A CN202180029571A CN115956086A CN 115956086 A CN115956086 A CN 115956086A CN 202180029571 A CN202180029571 A CN 202180029571A CN 115956086 A CN115956086 A CN 115956086A
Authority
CN
China
Prior art keywords
leu
ala
ser
gly
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180029571.6A
Other languages
English (en)
Chinese (zh)
Inventor
吴嘉茂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samoan Shangpai Biotech Co ltd
Original Assignee
Samoan Shangpai Biotech Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samoan Shangpai Biotech Co ltd filed Critical Samoan Shangpai Biotech Co ltd
Publication of CN115956086A publication Critical patent/CN115956086A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180029571.6A 2020-05-06 2021-04-26 用于针对癌症及传染病的免疫疗法的融合蛋白 Pending CN115956086A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063020545P 2020-05-06 2020-05-06
US63/020,545 2020-05-06
PCT/US2021/029203 WO2021225820A1 (fr) 2020-05-06 2021-04-26 Protéines de fusion d'immunothérapie contre le cancer et des maladies infectieuses

Publications (1)

Publication Number Publication Date
CN115956086A true CN115956086A (zh) 2023-04-11

Family

ID=78412282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180029571.6A Pending CN115956086A (zh) 2020-05-06 2021-04-26 用于针对癌症及传染病的免疫疗法的融合蛋白

Country Status (12)

Country Link
US (1) US20210347906A1 (fr)
EP (1) EP4146701A4 (fr)
JP (1) JP2023524814A (fr)
KR (1) KR20230008162A (fr)
CN (1) CN115956086A (fr)
AU (1) AU2021268885A1 (fr)
BR (1) BR112022021797A2 (fr)
CA (1) CA3172293A1 (fr)
IL (1) IL296880A (fr)
MX (1) MX2022013809A (fr)
TW (1) TWI817113B (fr)
WO (1) WO2021225820A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022380700A1 (en) * 2021-11-05 2024-04-18 Navicure Biopharmaceuticals Limited Immunogenic fusion proteins against infectious animal diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1563074B1 (fr) * 2002-11-12 2018-01-10 VAXum, LLC. Vaccin a vecteur adenoviral
PT2310509E (pt) * 2008-07-21 2015-05-19 Apogenix Gmbh Moléculas de tnfsf em cadeia simples
DK2928491T3 (en) * 2012-12-05 2019-01-14 Thevax Genetics Vaccine Co Ltd FUSION PROTEINS TO USE AS IMMUNOGENEOUS AMPLIFIERS FOR INduction OF ANTIGEN-SPECIFIC T-CELL RESPONSES
US10533054B2 (en) * 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
JP6735237B2 (ja) * 2014-06-11 2020-08-05 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. プロテアーゼ切断耐性、志賀毒素ａサブユニットエフェクターポリペプチド及びそれを含む細胞標的化分子
BR112017018017A2 (pt) * 2015-02-26 2018-04-10 Thevax Genetics Vaccine Co Ltd composição de vacina compreendendo uma proteína imunogênica e adjuvantes de combinação para uso na promoção de respostas de células t específicas de antigenos
MX2017013321A (es) * 2015-04-22 2018-07-06 Curevac Ag Composicion que contiene arn para tratamiento de enfermedades tumorales.
AU2016285913B2 (en) * 2015-06-29 2022-06-16 Bristol-Myers Squibb Company Antibodies to CD40
WO2017162797A1 (fr) * 2016-03-23 2017-09-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Protéines de fusion de pd-1 et 4-1 bb
US10058606B2 (en) * 2016-09-19 2018-08-28 Thevax Genetics Vaccine Co., Ltd. Hepatitis B therapeutic vaccines
WO2018213747A1 (fr) * 2017-05-19 2018-11-22 Merrimack Pharmaceuticals, Inc. Molécules bispécifiques agonistes de 4-1bb et de cd40

Also Published As

Publication number Publication date
KR20230008162A (ko) 2023-01-13
TWI817113B (zh) 2023-10-01
BR112022021797A2 (pt) 2022-12-13
TW202200625A (zh) 2022-01-01
CA3172293A1 (fr) 2021-11-11
EP4146701A1 (fr) 2023-03-15
EP4146701A4 (fr) 2024-05-15
MX2022013809A (es) 2022-11-30
JP2023524814A (ja) 2023-06-13
AU2021268885A1 (en) 2022-10-27
US20210347906A1 (en) 2021-11-11
WO2021225820A1 (fr) 2021-11-11
IL296880A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
JP6114237B2 (ja) 非溶血性ｌｌｏ融合タンパク質およびそれを利用する方法
ES2432357T3 (es) Anticuerpos enteramente humanos contra 4-1BB humano (CD137)
US7655238B2 (en) Compositions and methods for enhancing the immunogenicity of antigens
US7662396B2 (en) Compositions and methods for enhancing the immunogenicity of antigens
US7700344B2 (en) Compositions and methods for enhancing the immunogenicity of antigens
US20160220652A1 (en) Methods of using recombinant listeria vaccine strains in disease immunotherapy
CA2786940C (fr) Vaccin contre une tumeur impliquant une reponse immunitaire a mediation humorale et proteines associees, y compris l'ensemble ou une portion de la proteine antigene du noyau du virus b de l'hepatite et un epitope de claudin 18.2
TW201639594A (zh) 利用重組李斯特菌菌株之組合療法
TW201704464A (zh) 包含肽袖珍基因表現系統之以李斯特菌屬為主的組成物及其使用方法
Mohit et al. The contribution of NT‐gp96 as an adjuvant for increasing HPV16 E7‐specific immunity in C57BL/6 mouse model
Daemi et al. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model
CN107286244B (zh) 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
TWI817113B (zh) 用於針對癌症及傳染病之免疫療法之融合蛋白
EP2366709A1 (fr) Vaccination anti-tumeur impliquant une réponse immunitaire humorale contre les protéines endogènes
CN118201636A (zh) 抗癌症及感染性疾病的组合疗法
KR20240099343A (ko) 암 및 감염병에 대한 병용 요법
TW202413440A (zh) 針對感染性動物疾病的免疫性融合蛋白質
US20240141016A1 (en) Immunogenic fusion proteins against infectious animal diseases
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
KR20240099344A (ko) 감염성 동물 질환에 대한 면역원성 융합 단백질
TW202334182A (zh) 針對冠狀病毒的免疫原性融合蛋白
CN118265541A (en) Immunogenic fusion proteins against coronaviruses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination